Cyclin‑dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma

Deng,Yupeng; Han,Qun; Mei,Shuyu; Li,Hailing; Yang,Fan; Wang,Jun; Ge,Shuang; Jing,Xiaotong; Xu,Hui; Zhang,Tingguo

doi:10.3892/ol.2019.10668

Cyclin‑dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma

Authors:
- Yupeng Deng
- Qun Han
- Shuyu Mei
- Hailing Li
- Fan Yang
- Jun Wang
- Shuang Ge
- Xiaotong Jing
- Hui Xu
- Tingguo Zhang
View Affiliations

Affiliations: Institute of Pathology and Pathophysiology, Shandong University School of Medicine, Jinan, Shandong 250012, P.R. China, Department of Pathology, Qilu Hospital of Shandong University, Qingdao, Shandong 266035, P.R. China
Published online on: July 25, 2019 https://doi.org/10.3892/ol.2019.10668
Pages: 2845-2852
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclin‑dependent kinase subunit (CKS) 2 is a member of the CKS family, which plays an important role in the regulation of meiosis and mitosis. Overexpression of CKS2 has been reported in several types of tumors. However, few studies have investigated its role in uterine leiomyosarcoma (ULMS). In the present study, the expression of CKS2 in 38 cases of ULMS and 38 cases of uterine leiomyoma (ULM) was analyzed by immunohistochemistry. Moreover, the functional analysis of CKS2 was performed in ULMS cell lines. A significantly higher expression of CKS2 was found in ULMS tissues than in ULM tissues (P<0.01) and high CKS2 expression was associated with increased tumor size, low progesterone receptor expression and poor prognosis in patients with ULMS. Multivariate Cox regression analysis revealed that CKS2 expression status was an independent predictor of overall survival for ULMS. Furthermore, silencing of CKS2 in ULMS cells inhibited cell proliferation, colony formation, migration and invasion, and resulted in cell cycle arrest. In conclusion, the present study demonstrated that CKS2 may serve as a marker for the differential diagnosis of ULMS and ULM. In addition, it may act as an independent prognostic factor in patients with ULMS, and serve as a novel target for ULMS therapy.

View Figures

View References

1	Hensley ML, Barrette BA, Baumann K, Gaffney D, Hamilton AL, Kim JW, Maenpaa JU, Pautier P, Siddiqui NA, Westermann AM and Ray-Coquard I: Gynecologic cancer intergroup (GCIG) consensus review: Uterine and ovarian leiomyosarcomas. Int J Gynecol Cancer. 24 (Suppl 3):S61–S66. 2014. View Article : Google Scholar : PubMed/NCBI
2	Giuntoli RL II, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL and Gostout BS: Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 89:460–469. 2003. View Article : Google Scholar : PubMed/NCBI
3	Kapp DS, Shin JY and Chan JK: Prognostic factors and survival in 1,396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 112:820–830. 2008. View Article : Google Scholar : PubMed/NCBI
4	Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM and Kristensen GB: Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 54:355–364. 2009. View Article : Google Scholar : PubMed/NCBI
5	Gockley AA, Rauh-Hain JA and del Carmen MG: Uterine leiomyosarcoma: A review article. Int J Gynecol Cancer. 24:1538–1542. 2014. View Article : Google Scholar : PubMed/NCBI
6	Miller H, Ike C, Parma J, Masand RP, Mach CM and Anderson ML: Molecular targets and emerging therapeutic options for uterine leiomyosarcoma. Sarcoma. 2016:70181062016. View Article : Google Scholar : PubMed/NCBI
7	Richardson HE, Stueland CS, Thomas J, Russell P and Reed SI: Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe. Genes Dev. 4:1332–1344. 1990. View Article : Google Scholar : PubMed/NCBI
8	Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M and Hershko A: The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol. 3:321–324. 2001. View Article : Google Scholar : PubMed/NCBI
9	Martinsson-Ahlzén HS, Liberal V, Grünenfelder B, Chaves SR, Spruck CH and Reed SI: Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Mol Cell Biol. 28:5698–5709. 2008. View Article : Google Scholar : PubMed/NCBI
10	Spruck CH, de Miguel MP, Smith AP, Ryan A, Stein P, Schultz RM, Lincoln AJ, Donovan PJ and Reed SI: Requirement of cks2 for the first metaphase/anaphase transition of mammalian meiosis. Science. 300:647–650. 2003. View Article : Google Scholar : PubMed/NCBI
11	Wang J, Xu L, Liu Y, Chen J, Jiang H, Yang S and Tan H: Expression of cyclin kinase subunit 2 in human breast cancer and its prognostic significance. Int J Clin Exp Pathol. 7:8593–8601. 2014.PubMed/NCBI
12	Wang JJ, Fang ZX, Ye HM, You P, Cai MJ, Duan HB, Wang F and Zhang ZY: Clinical significance of overexpressed cyclin-dependent kinase subunits 1 and 2 in esophageal carcinoma. Dis Esophagus. 26:729–736. 2013.PubMed/NCBI
13	Tanaka F, Matsuzaki S, Mimori K, Kita Y, Inoue H and Mori M: Clinicopathological and biological significance of CDC28 protein kinase regulatory subunit 2 overexpression in human gastric cancer. Int J Oncol. 39:361–372. 2011.PubMed/NCBI
14	Yu MH, Luo Y, Qin SL, Wang ZS, Mu YF and Zhong M: Up-regulated CKS2 promotes tumor progression and predicts a poor prognosis in human colorectal cancer. Am J Cancer Res. 5:2708–2718. 2015.PubMed/NCBI
15	Shen DY, Fang ZX, You P, Liu PG, Wang F, Huang CL, Yao XB, Chen ZX and Zhang ZY: Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Liver Int. 30:119–125. 2010. View Article : Google Scholar : PubMed/NCBI
16	Shen DY, Zhan YH, Wang QM, Rui G and Zhang ZM: Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma. Liver Int. 33:137–148. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kawakami K, Enokida H, Tachiwada T, Gotanda T, Tsuneyoshi K, Kubo H, Nishiyama K, Takiguchi M, Nakagawa M and Seki N: Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling. Oncol Rep. 16:521–531. 2006.PubMed/NCBI
18	Walker RA: World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Histopathology. 46:229. 2005. View Article : Google Scholar
19	Prat J: FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 104:177–178. 2009. View Article : Google Scholar : PubMed/NCBI
20	Coley HM, Shotton CF, Kokkinos MI and Thomas H: The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines. Gynecol Oncol. 105:462–469. 2007. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Qi J, Yu Y, Akilli Öztürk Ö, Holland JD, Besser D, Fritzmann J, Wulf-Goldenberg A, Eckert K, Fichtner I and Birchmeier W: New Wnt/β-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals. Gut. 65:1690–1701. 2016. View Article : Google Scholar : PubMed/NCBI
23	Cui RR, Wright JD and Hou JY: Uterine leiomyosarcoma: A review of recent advances in molecular biology, clinical management and outcome. BJOG. 124:1028–1037. 2017. View Article : Google Scholar : PubMed/NCBI
24	Cuppens T, Tuyaerts S and Amant F: Potential therapeutic targets in uterine sarcomas. Sarcoma. 2015:2432982015. View Article : Google Scholar : PubMed/NCBI
25	Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S and Ladanyi M: Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 11:541–557. 2011. View Article : Google Scholar : PubMed/NCBI
26	Mäkinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto-Korander R, Bützow R and Vahteristo P: Exome sequencing of uterine leiomyosarcomas identifies frequent mutations in tp53, atrx, and med12. PLoS Genet. 12:e10058502016. View Article : Google Scholar : PubMed/NCBI
27	You H, Lin H and Zhang Z: CKS2 in human cancers: Clinical roles and current perspectives (Review). Mol Clin Oncol. 3:459–463. 2015. View Article : Google Scholar : PubMed/NCBI
28	Koivisto-Korander R, Martinsen JI, Weiderpass E, Leminen A and Pukkala E: Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: Results from NORDCAN and NOCCA databases. Maturitas. 72:56–60. 2012. View Article : Google Scholar : PubMed/NCBI